Results 121 to 130 of about 2,835 (182)

Filgotinib in the treatment of infl ammatory bowel diseases

Gastroenterologie a hepatologie, 2023
openaire   +1 more source

Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis. [PDF]

Front Pharmacol
Wu H, Zhou Y, Chen X, Wang L, Guo Y, Du X, Miao X.   +6 more
europepmc   +1 more source

A meta-analysis of the efficacy and safety of Janus kinase inhibitors in patients with ulcerative colitis. [PDF]

Medicine (Baltimore)
Yang Q, Yan Y.
europepmc   +1 more source

Safety and efficacy of long-term filgotinib treatment in Japanese patients with ulcerative colitis: an interim subgroup analysis of the SELECTION long-term extension study. [PDF]

Crohns Colitis 360
Matsuoka K, Hata E, Kaise T, Rudolph C, Hibi T.   +4 more
europepmc   +1 more source

The JAK1-STAT1 signaling pathway triggers inflammation responses in chronic obstructive sleep apnea rat model. [PDF]

PLoS One
Yang L, He J.
europepmc   +1 more source

Real-World Comparative Efficacy and Safety of Upadacitinib, Tofacitinib, and Filgotinib in Patients With Ulcerative Colitis. [PDF]

Cureus
Ahmad F, Hussain T, Gunaratne CH, Collum J, Ghaffar A, Gharbia K.   +5 more
europepmc   +1 more source

Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA). [PDF]

Rheumatol Ther
Pongratz G, Alten R, Witte T, Pausch C, Reinhold R, Pittrow D, Burmester GR.   +6 more
europepmc   +1 more source

Long-term clinical outcomes with filgotinib in ulcerative colitis: 12-month results from the FILGUITO study. [PDF]

World J Gastroenterol
Caballero-Mateos AM, Trigo-Salado C, Suárez-Toribio Á, Martín-Rodríguez MDM, Rodríguez-González FJ, Valdés-Delgado T, Pallarés-Manrique H, Trapero-Martínez AM, Olmedo-Martín R, Bailón-Gaona C, Benitez Cantero JM, Gros B, Sáez-Díaz A, Hernández-Martínez Á.   +13 more
europepmc   +1 more source

Filgotinib in Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis of Efficacy and Adverse Events. [PDF]

Healthcare (Basel)
Khoshaim YA, Habis YZ, Daqnah AG, Alqurashi RK, Abdulrahim YS, Sakkat A, Alsubhi SA, Almuwlad DT, Bukhari HS, Shogdar AJ, Amir OA, Zaazouee MS.   +11 more
europepmc   +1 more source

Revisiting Janus kinases as molecular drug targets for rheumatic diseases. [PDF]

Front Med (Lausanne)
Kwon S.
europepmc   +1 more source